{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:50:01Z","timestamp":1754153401158,"version":"3.41.2"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1136\/ijgc-2018-000055","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T14:11:48Z","timestamp":1547475108000},"page":"147-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Sarah E","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S","family":"Petschauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Schorzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Razo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin K","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2018-000055_bb0010","article-title":"Ovarian cancer statistics, 2018","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2018-000055_bb0015","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2018-000055_bb0020","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2018-000055_bb0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2018-000055_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2018-000055_bb0035","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2018-000055_bb0040","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ygyno.2015.06.026","article-title":"Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer","volume":"138","author":"Taylor","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"Pt 1","key":"10.1136\/ijgc-2018-000055_bb0045","first-page":"5896","article-title":"Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics","volume":"9","author":"Morgan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2018-000055_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0731-7085(00)00377-0","article-title":"Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin","volume":"24","author":"Morrison","year":"2000","journal-title":"J Pharm Biomed Anal"},{"key":"10.1136\/ijgc-2018-000055_bb0055","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00280-002-0531-6","article-title":"Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat","volume":"50","author":"Liu","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1136\/ijgc-2018-000055_bb0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jchromb.2004.01.021","article-title":"Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry","volume":"804","author":"Hou","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1136\/ijgc-2018-000055_bb0065","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1570-0232(02)00659-1","article-title":"Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma","volume":"783","author":"Parise","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1136\/ijgc-2018-000055_bb0070","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2018-000055_bb0075","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jpainsymman.2007.04.017","article-title":"Evaluation of the Symptom Representation Questionnaire (SRQ) for assessing cancer-related symptoms","volume":"35","author":"Donovan","year":"2008","journal-title":"J Pain Symptom Manage"},{"key":"10.1136\/ijgc-2018-000055_bb0080","first-page":"918","article-title":"Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer","volume":"96","author":"Nicoletto","year":"2010","journal-title":"Tumori"},{"key":"10.1136\/ijgc-2018-000055_bb0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/gyno.2000.5793","article-title":"Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up","volume":"77","author":"Morgan","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000055_bb0090","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/IGC.0b013e318234f833","article-title":"Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes","volume":"22","author":"Skaznik-Wikiel","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2018-000055_bb0095","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000443924","article-title":"Second-line intraperitoneal chemotherapy for recurrent epithelial ovarian, tubal and peritoneal cancer: a propensity score-matching study","volume":"61","author":"Lu","year":"2016","journal-title":"Chemotherapy"},{"key":"10.1136\/ijgc-2018-000055_bb0100","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2017.03.013","article-title":"Second-line intraperitoneal chemotherapy for recurrent epithelial ovarian, tubal and peritoneal cancer: a propensity score-matching study","volume":"145","author":"Jandial","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000055_bb0105","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/IGC.0000000000000667","article-title":"Second-line intraperitoneal platinum-based therapy leads to an increase in second-line progression-free survival for epithelial ovarian cancer","volume":"26","author":"Boisen","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl 1","key":"10.1136\/ijgc-2018-000055_bb0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1525-1438.2007.01099.x","article-title":"Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer","volume":"18","author":"Howell","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2018-000055_bb0115","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","article-title":"Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2018-000055_bb0120","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","article-title":"Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study","volume":"13","author":"Francis","year":"1995","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24010338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24010338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2018-000055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:24:05Z","timestamp":1753233845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24010338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1048891X24010338"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2018-000055","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2018-000055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}